New report indicates more than 10% of the UK’s top female BioBusiness talent is based at Stevenage Bioscience Catalyst

A new report released today by BioBeat entitled “50 Movers & Shakers in BioBusiness 2019” includes five women from organisations based at Stevenage Bioscience Catalyst (SBC) as well as two Board members. The report highlights the top female talent in the pharma and biotech sectors within the UK.

The report focuses on the impact of individuals in five key areas, namely science, finance, collaboration, patient impact and infrastructure. The SBC-based individuals which spanned the segments are:

• Sally Ann Forsyth, CEO, Stevenage Bioscience Catalyst
• Veronique Bouchet, Chief Medical Officer, RowAnalytics and SBC Board member
• Melanie Lee, CEO, LifeArc
• Jane Whitrow, VP Business Operations, Freeline Therapeutics
• Pauline Stasiak, Investment Principal, LifeArc Seed Fund
• Jane Robertson, Chief Medical Officer, Achilles Therapeutics
• Anna Outhwaite, Head, ATTC Network Coordination, Cell and Gene Therapy Catapult

The 50 Movers and Shakers report has been released in advance of the BioBeat19 Summit: Accelerating Cell and Gene Therapy, which will be hosted by GSK and SBC on Tuesday 19 November 2019. Emma Walmsley, CEO at GSK will deliver the keynote address, followed by discussions with leading women from across the cell and gene therapy landscape examining the journey from science to patients, and the value of these transformational therapies.

Dr Sally Ann Forsyth, CEO at SBC, commented “It is an honour to be included amongst this list of exceptional women from across the sector. We are proud that SBC is home to so many of this year’s Movers and Shakers. I look forward to further showcasing our talents when we co-host the BioBeat19 event later this month.”

--------------------------------------------------------------------------------------------------------------------------------

Notes to the Editor

Stevenage Bioscience Catalyst

Stevenage Bioscience Catalyst is a world-leading science park of global significance and home to the largest cluster of cell and gene therapy companies in Europe. Since its opening in 2012, it has attracted over 40 high-profile occupier businesses and world-class research organisations to Stevenage. This includes the Cell and Gene Therapy Catapult Manufacturing Centre which is currently undergoing expansion to help support up to 12 cell and gene therapy companies. Occupiers of the SBC campus have raised almost £1bn of investment, of which around 60% has been invested into cell and gene therapy companies.

BioBeat

BioBeat connects entrepreneurs with leaders in biotech, by working to respond to challenges and open opportunities through the inspirational experience of women leaders. Miranda Weston-Smith founded BioBeat to bring fresh energy and insights into biotech for a healthier world.

BioBeat has produced the 50 Movers & Shakers in BioBusiness report every year since 2014, identifying outstanding female leadership talent in UK bioscience. The annual BioBeat summit brings together pioneers in biotech to nurture innovation and forge new partnerships.

Find out more at https://www.mws-consulting.co.uk/biobeat/

Media Contact Information: 

Claire Thompson on behalf of SBC
claire.thompson@agilityhealthtech.com
+44 (0)7885 591 187
www.stevenagecatalyst.com